A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses

Document Details

Document Type
Pub Defense Publication
Publication Date
Oct 01, 2023
Source ID
10.1016/j.vaccine.2023.07.040

Entities

People

  • Ann M. Greene
  • Bethanie Wilkinson
  • Chengbin Wang
  • Emily R. Smith
  • Gale Smith
  • Katherine Smith
  • Kinjal S. Patel
  • Marc Gurwith
  • Robert A Walker
  • Robert T. Chen

Organizations

  • Biomedical Advanced Research and Development Authority
  • Centers for Disease Control and Prevention
  • Coalition for Epidemic Preparedness Innovations
  • Food and Drug Administration
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health
  • United States Department of Defense
  • United States Department of Health and Human Services

Tags

Technology Areas

  • Biotechnology